{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:47Z","timestamp":1789958867070,"version":"4.0.1"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.03180","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:56:27Z","timestamp":1547787387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells"],"prefix":"10.3389","volume":"9","author":[{"given":"Alka","family":"Dwivedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atharva","family":"Karulkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbari","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrin","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Purwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell Therapy: a new era in cancer immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr Pharm Biotechnol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","article-title":"The association of heavy and light chain variable domains in antibodies: implications for antigen specificity","volume":"278","author":"Chailyan","year":"2011","journal-title":"FEBS J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.coi.2008.06.004","article-title":"Fully human antibodies from transgenic mouse and phage display platforms","volume":"20","author":"Lonberg","year":"2008","journal-title":"Curr Opin Immunol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-62703-293-3_6","article-title":"In vitro evolution of enzymes","volume-title":"Enzyme Engineering.","author":"Golynskiy","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymeth.2012.03.008","article-title":"In vitro selection of proteins via emulsion compartments","volume":"60","author":"Lu","year":"2013","journal-title":"Methods"},{"key":"B10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nmeth1003","article-title":"Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target","volume":"4","author":"Zahnd","year":"2007","journal-title":"Nat Methods"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/nbt1126","article-title":"Selecting and screening recombinant antibody libraries","volume":"23","author":"Hoogenboom","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.febslet.2013.11.025","article-title":"Therapeutic antibody engineering by high efficiency cell screening","volume":"588","author":"Doerner","year":"2014","journal-title":"FEBS Lett."},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0958-1669(00)00233-0","article-title":"Protein engineering by cell-surface display","volume":"12","author":"Wittrup","year":"2001","journal-title":"Curr Opin Biotechnol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.2910390306","article-title":"Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity","volume":"39","author":"Miotti","year":"1987","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Molecular Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Hudecek","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"James","year":"2008","journal-title":"J Immunol."},{"key":"B28","first-page":"218","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Am Soc Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med."},{"key":"B31","first-page":"5430","article-title":"Preclinical analyses support clinical investigation of combined PD-L1 blockade and anti-CD19 CAR T cell therapy for the treatment of NHL","volume":"126","author":"Larson","year":"2015","journal-title":"Am Soc Hematol."},{"key":"B32","first-page":"SCI-15","article-title":"Enhancing the efficacy of CAR T cells","volume":"130","author":"Mackall","year":"2017","journal-title":"Am Soc Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest."},{"key":"B36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J Immunother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","article-title":"Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells","volume":"10","author":"Qin","year":"2017","journal-title":"J Hematol Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"B40","first-page":"2377","article-title":"Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes","volume":"32","author":"Shirasu","year":"2012","journal-title":"Anticancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/hum.2009.122","article-title":"4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies","volume":"21","author":"Tammana","year":"2010","journal-title":"Hum Gene Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14336","DOI":"10.1073\/pnas.1221740110","article-title":"CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability","volume":"110","author":"van","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/hum.2012.247","article-title":"Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation","volume":"24","author":"Hombach","year":"2013","journal-title":"Hum Gene Ther."},{"key":"B56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nri.2018.8","article-title":"Immunotherapy: cytokine boost for CAR T cells","volume":"18","author":"Minton","year":"2018","journal-title":"Nat Rev Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"82354","DOI":"10.18632\/oncotarget.10510","article-title":"Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcyt.2017.06.003","article-title":"Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion","volume":"19","author":"Kaartinen","year":"2017","journal-title":"Cytotherapy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol."},{"key":"B69","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy","volume":"16","author":"Sportes","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"7226","DOI":"10.4049\/jimmunol.175.11.722","article-title":"Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine","volume":"175","author":"Hsu","year":"2005","journal-title":"J Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1182\/blood-2006-06-029173","article-title":"Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene","volume":"109","author":"Hsu","year":"2007","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/S1525-0016(16)33208-7","article-title":"399. Evaluation of CD123 targeting CART Cells in non-human primates","volume":"24","author":"Dong","year":"","journal-title":"Mol Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/mt.2016.146","article-title":"Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma","volume":"24","author":"Panjwani","year":"2016","journal-title":"Mol Ther."}],"updated-by":[{"DOI":"10.3389\/fimmu.2019.00401","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T08:19:11Z","timestamp":1552033151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.03180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2018.03180"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.03180","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2019.00401","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"article-number":"3180"}}